Nestle invests $200 million more in Aimmune after peanut allergy drug approval
Share:
(Reuters) - Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.The funding brings Nestle's total investment to $473 million, increasing the Swiss company's stake to 19.9% of Aimmune's outstanding stock and voting power.Aimmune shares rose 5.7% in early morning trading, after falling 11% on Tuesday. Its therapy,..